AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

benzinga.com/general/biotech/25/05/45168310/astrazenecas-triple-combination-therapy-breztri-hits-primary-goals-in-two-pivotal-studies-for-ast

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma.
KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two…

This story appeared on benzinga.com, 2025-05-02 14:18:10.
The Entire Business World on a Single Page. Free to Use →